TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00261456

Intervention type: DIAGNOSTIC_TEST
Intervention: PSA test
Description: Patients tested for their level of Prostate Specific Antigen.

Intervention type: DIAGNOSTIC_TEST
Intervention: PSA test
Description: Patients tested for their level of Prostate Specific Antigen.

Intervention type: DIAGNOSTIC_TEST
Intervention: PSA test
Description: Patients tested for their level of Prostate Specific Antigen.

Intervention type: DIAGNOSTIC_TEST
Intervention: PSA test
Description: Patients tested for their level of Prostate Specific Antigen.

Intervention type: PROCEDURE
Intervention: Prostate Biopsy
Description: A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.

Intervention type: PROCEDURE
Intervention: Prostate Biopsy
Description: A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.

Intervention type: PROCEDURE
Intervention: Prostate Biopsy
Description: A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.

Intervention type: PROCEDURE
Intervention: Prostate Biopsy
Description: A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
Study: NCT02465515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg
Description: Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Description: Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Albiglutide matching placebo
Description: Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
Study: NCT02573688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Therapy
Description: The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
Study: NCT02014571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
Study: NCT02852707

Intervention type: BEHAVIORAL
Intervention: Chronic exposure to unilateral overhead sports activity
Description: Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports).
Study: NCT01019616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel/anthracycline
Description: standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
Study: NCT02852707

Intervention type: BEHAVIORAL
Intervention: Chronic exposure to bilateral overhead sports activity
Description: Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports).

Intervention type: BEHAVIORAL
Intervention: Not exposed
Description: People not engaged in regular sports competition/exercise training.
Study: NCT02533167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin to skin
Description: initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
Study: NCT02014571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
Study: NCT02620657

Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study: NCT01688518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heated Lidocaine/Tetracaine Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heated Lidocaine/Tetracaine Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Lidocaine Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Lidocaine Patch
Study: NCT01817530

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix placebo
Description: oral coated tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix placebo
Description: oral coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: oral coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: oral coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: oral coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: oral coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: oral coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: oral coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol / 0.1 mg norethindrone acetate
Description: oral hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol / 0.1 mg norethindrone acetate
Description: oral hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol / 0.5 mg norethindrone acetate
Description: oral hard capsule
Study: NCT02311504

Intervention type: DEVICE
Intervention: OCT examination
Study: NCT01817530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol / 0.5 mg norethindrone acetate
Description: oral hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/NETA placebo
Description: oral hard capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2/NETA placebo
Description: oral hard capsule
Study: NCT06442410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTM™ spinal cord stimulation therapy delivered via Intellis™ neurostimulator system
Description: Along with the appropriate Conventional Medical Management treatment made by the Investigator, the subject will be trialed and implanted with an Intellis™ neurostimulator system using DTM™ SCS programming parameters.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management (CMM)
Description: The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Medical Management (CMM)
Description: The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar
Study: NCT01659151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Interleukin-2 (IL-2)
Description: A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACT with TIL Infusion
Description: Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepletion
Description: The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion.
Study: NCT01817530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/NETA placebo
Description: oral hard capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2/NETA placebo
Description: oral hard capsule
Study: NCT01044875

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pan retinal photocoagulation laser treatment
Description: Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pan retinal photocoagulation laser treatment
Description: Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
Study: NCT02538029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task Group
Description: Performing motor-motor or motor-cognitive tasks at the same time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Task Group
Description: Performing motor or cognitive tasks alone.
Study: NCT00492141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Cycle 2, Dose Level 1 = 100 mg/m\^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m\^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9-NC
Description: Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3.
Study: NCT04335097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosensors
Description: Sensor that detect vital signs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosensors
Description: Sensor that detect vital signs
Study: NCT04760821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Trimetazidine 35mg bid in patients with GFR above 60mL/min. Trimetazidine 35mg od in patients with GFR between 30 and 60mL/min.
Study: NCT01861860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS™ Element long stent
Description: Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain \> 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
Study: NCT01673217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 peptide vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study: NCT03436485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-208
Description: co-administered with glucocorticoid and fludrocortisone, orally daily
Study: NCT01673217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study: NCT02702219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility of the hamstrings muscles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobility of the hamstrings muscles
Study: NCT00507923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: Wear actigraph

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph
Description: Wear actigraph

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph
Description: Wear actigraph

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Diary
Description: Complete sleep diary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Diary
Description: Complete sleep diary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Diary
Description: Complete sleep diary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participate in stretching sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participate in Tibetan yoga
Study: NCT00713856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Custom PRK with iris registration
Description: PRK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PRK
Description: PRK
Study: NCT00214760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PGET
Description: resolbable liner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMMA
Description: cement liner
Study: NCT02777333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
Study: NCT02597231

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin is the dietary supplement we are using in delirium prevention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive a matching placebo pill.
Study: NCT00981240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR103168
Description: Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion
Study: NCT02210650

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Symptomatic stone removal
Description: Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Asymptomatic kidney stones and ureteral stone removed
Description: Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
Study: NCT03436485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-208
Description: co-administered with glucocorticoid and fludrocortisone, orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-208
Description: co-administered with glucocorticoid and fludrocortisone, orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: orally
Study: NCT03205527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground slip perturbation training
Description: Slips will be induced by a low-friction platform (65×30×0.6 cm, μ\<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground slip perturbation training
Description: Slips will be induced by a low-friction platform (65×30×0.6 cm, μ\<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
Study: NCT02166463

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin Sulfate
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies